Katherine Webber1, Andrew N Davies2, Giovambattista Zeppetella3, Martin R Cowie4. 1. Imperial College London, London, United Kingdom; Royal Surrey County Hospital, Guildford, United Kingdom; Royal Marsden Hospital, London, United Kingdom. Electronic address: kath@kathwebber.com. 2. Imperial College London, London, United Kingdom; Royal Surrey County Hospital, Guildford, United Kingdom. 3. St. Clare Hospice, Hastingwood, United Kingdom. 4. Imperial College London, London, United Kingdom.
Abstract
CONTEXT: The successful management of breakthrough pain depends on a combination of adequate assessment, appropriate (individualized) treatment, and adequate re-assessment. Currently, there is no fully validated clinical assessment tool for breakthrough pain in cancer patients. OBJECTIVES: The aim of this project was to develop and validate a breakthrough pain assessment tool (the BAT) for use in the clinical setting. METHODS: The content of the BAT was determined by reviewing the medical literature, conducting a Delphi process with experts in breakthrough pain and/or pain assessment and conducting semi-structured interviews with cancer patients with breakthrough pain. The tool was then subjected to a series of standard psychometric tests to assess its factor structure, validity (i.e., content validity, construct validity), reliability (i.e., internal consistency, test-retest reliability), and responsiveness to change. RESULTS: The BAT comprised two pages with 14 questions. Factor analysis confirmed the presence of two underlying factors. Psychometric testing confirmed that the tool is valid, reliable, and responsive to change. CONCLUSION: This study provides initial evidence for the validity and reliability of the breakthrough pain assessment tool which may be used to facilitate the management of patients with breakthrough cancer pain in the clinical setting.
CONTEXT: The successful management of breakthrough pain depends on a combination of adequate assessment, appropriate (individualized) treatment, and adequate re-assessment. Currently, there is no fully validated clinical assessment tool for breakthrough pain in cancerpatients. OBJECTIVES: The aim of this project was to develop and validate a breakthrough pain assessment tool (the BAT) for use in the clinical setting. METHODS: The content of the BAT was determined by reviewing the medical literature, conducting a Delphi process with experts in breakthrough pain and/or pain assessment and conducting semi-structured interviews with cancerpatients with breakthrough pain. The tool was then subjected to a series of standard psychometric tests to assess its factor structure, validity (i.e., content validity, construct validity), reliability (i.e., internal consistency, test-retest reliability), and responsiveness to change. RESULTS: The BAT comprised two pages with 14 questions. Factor analysis confirmed the presence of two underlying factors. Psychometric testing confirmed that the tool is valid, reliable, and responsive to change. CONCLUSION: This study provides initial evidence for the validity and reliability of the breakthrough pain assessment tool which may be used to facilitate the management of patients with breakthrough cancer pain in the clinical setting.
Authors: Sebastiano Mercadante; Paolo Marchetti; Arturo Cuomo; Massimo Mammucari; Augusto Caraceni Journal: Support Care Cancer Date: 2015-10-05 Impact factor: 3.603
Authors: R Vellucci; G Fanelli; R Pannuti; C Peruselli; S Adamo; G Alongi; F Amato; L Consoletti; L Lamarca; S Liguori; C Lo Presti; A Maione; S Mameli; F Marinangeli; S Marulli; V Minotti; D Miotti; L Montanari; G Moruzzi; S Palermo; M Parolini; P Poli; W Tirelli; A Valle; P Romualdi Journal: Drugs Date: 2016-03 Impact factor: 9.546
Authors: Katie Greenfield; Simone Holley; Daniel Eric Schoth; Julie Bayliss; Anna-Karenia Anderson; Satbir Jassal; Dilini Rajapakse; Lorna Katharine Fraser; Christine Mott; Margaret Johnson; Ian Wong; Richard Howard; Emily Harrop; Christina Liossi Journal: BMJ Open Date: 2020-03-29 Impact factor: 2.692